Evolent Health Q2 revenue up 44% to $319.9M; closes IPG acquisition

Evolent Health, Inc.

2022-Q2 EPS reported -$0.11 revenue$319,939,000

Revenue of $319.9M, +44.1% YoY; Adjusted EBITDA of $21.7M (6.8% margin).
Net loss attributable to common shareholders of $4.6M.
Total Lives on Platform 21.9M as of June 30, 2022.
Added 4 new operating partnerships, including Molina Healthcare and a midwestern BCBS plan.
Closed acquisition of Implantable Provider Group (IPG), financed with $175M term loan and $50M revolver.

item 1.01 item 2.02 item 2.03 item 3.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Aammaad Shams

Chief Accounting Officer and Controller

EVH · Evolent Health, Inc.

Effective: 2022-08-01
Filed: August 2, 2022, 7:59 PM ET

On July 28, 2022, the Company promoted Aammaad Shams, age 38, who has been serving as Interim Principal Accounting Officer and Corporate Controller of the Company, to the position of the Company’s Chief Accounting Officer and Controller, effective August 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Aammaad Shams changed role as Chief Accounting Officer and Controller at Evolent Health, Inc..

Action: promoted
Role: Chief Accounting Officer and Controller

Exact text from the filing

On July 28, 2022, the Company promoted Aammaad Shams, age 38, who has been serving as Interim Principal Accounting Officer and Corporate Controller of the Company, to the position of the Company’s Chief Accounting Officer and Controller, effective August 1, 2022.

View on SEC.gov

Evolent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628908-22-000093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.